Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse.
Fiche publication
Date publication
juin 2016
Journal
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ANTONI Delphine, Dr CLAVIER Jean-Baptiste, Pr NOEL Georges, Dr SCHOTT Roland
Tous les auteurs :
Antoni D, Jastaniah Z, Haoming QC, Gaultier C, Ahle G, Couchot J, Atlani D, Schott R, Clavier JB, Srour R, Chaussemy D, Noël G
Lien Pubmed
Résumé
Bevacizumab and stereotactic treatment are efficient combined or alone in relapse glioma. However, patterns of relapse after this kind of salvage treatment have never been studied. The purpose of this unicentric retrospective analysis was to assess and understand the patterns of relapse of high grade glioma treated with stereotactic radiation, with or without bevacizumab.
Mots clés
Adult, Aged, Aged, 80 and over, Antineoplastic Agents, therapeutic use, Bevacizumab, therapeutic use, Brain Neoplasms, mortality, Camptothecin, analogs & derivatives, Chemotherapy, Adjuvant, Dacarbazine, analogs & derivatives, Female, Follow-Up Studies, Glioma, mortality, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, pathology, Radiation-Sensitizing Agents, therapeutic use, Radiosurgery, Radiotherapy, Adjuvant, Re-Irradiation, Retrospective Studies
Référence
Cancer Radiother. 2016 Jun;20(4):282-91